SEC Form 4 · accession 0001859453-26-000015
Vera Therapeutics, Inc. · VERA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marshall Fordyce
Officer — PRESIDENT AND CEO · Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 4:28 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001831828
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Sep 15, 2026 | M | 18,500 | $2.8968 | A | 253,744 | D | |
| Class A Common Stock | Sep 15, 2026 | S | 18,500 | $37.00 | D | 235,244 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.8968 | Sep 15, 2026 | M | 18,500 | D | — | Dec 15, 2030 | Class A Common Stock | 18,500 | 488,801 | D |
Explanation of responses
- F1The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F21/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.